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Dear Editor, Incidence of vulval squamous cell carcinoma in women with vulval lichen sclerosus in an Australian tertiary referral centre
Vulval lichen sclerosus (VLS) is a chronic inflammatory dermatitis of unknown aetiology associated with an increased risk of the development of genital squamous cell carcinoma (SCC) and scarring, with loss of vulval architecture and normal function. 1 Reported SCC rates range from 1-6%. [1] [2] [3] [4] [5] Current treatment guidelines recommend the use of a super-potent topical corticosteroid once or twice daily for 4 weeks, then on alternate days for 4 weeks, then twice weekly for 4 weeks, before review. 6 There is little evidence or consensus on the best practice for maintenance therapy. 6, 7 A recent study found a significantly reduced incidence of SCC in patients who complied with a topical corticosteroid application at least three times per week, regardless of symptoms (0%), compared with partially compliant patients (5%). 7 Treatment guidelines for women with VLS attending the tertiary referral vulval clinic at our hospital recommend a standard initiation therapy with a super-potent topical corticosteroid for achieving disease control, 6 then maintenance therapy using the minimum topical corticosteroid required to remain symptom free and have no evidence of active disease (such as purpura, hyperkeratosis or fissures) at the 4-12 monthly follow up. We conducted a retrospective single-centre review of all patients seen with VLS from 10 July 2012 to 5 April 2016 to determine the incidence of vulval intraepithelial neoplasia (VIN) or SCC. In total, 504 patients with a clinically or histopathologically confirmed diagnosis of VLS were seen during the study period. Patients with VIN or SCC at presentation were excluded (n = 38). The mean age of the VIN/SCC diagnosis was 65 years (56-77). A total of five women developed VIN/SCC, of whom two developed differentiated VIN, two usual VIN and one SCC, developing from usual VIN ( Table 1 ). The incidence of VLS-associated VIN was 2/ 466 (0.4%) and none developed VLS-associated SCC. The mean time to the development of VIN/SCC during routine follow ups was 4.5 years (0.5-8 years). The patient who developed SCC had been treated for VLS 2 and 8 years prior to developing usual VIN and SCC, respectively. All five patients were being followed up 6-monthly and used a topical corticosteroid at least twice weekly ( Table 1) .
The incidence of VLS-associated VIN/SCC in our cohort was 0.4%, which is considerably lower than that previously reported (1-6%).
1,3-5 Carlson and colleagues reported a pooled incidence of 5% (140/3093) from 22 studies. 8 More recent studies report much lower SCC incidence rates of from 1 to 3%. 9,10 Lee and colleagues reported an incidence of 0% during the long-term follow up of 357 women who were complaint with long-term maintenance topical corticosteroid treatment over 4.7 years. 7 The aetiology of vulval SCC is not fully understood. Known risk factors include VLS, human papilloma virus infection, history of VIN and smoking. [8] [9] [10] Other possible risk factors include disease severity, response to treatment, genetic predisposition and immune status. 10 SCC in the setting of VLS is associated with differentiated VIN and considered to be unrelated to human papilloma virus. 9 Women with VLS and differentiated VIN carry a greater risk of developing SCC than the general population. 9 In our study only two patients developed VLS-associated differentiated VIN and three human papilloma virus-associated usual VIN, one of whom went on to develop SCC. This study has several limitations that may have resulted in an underestimate of the incidence of VIN/SCC. Firstly, including patients with a clinical rather than histopathologically confirmed diagnosis of VLS may have lead to the inclusion of patients with vulval conditions that carry a lower carcinogenic risk. However, the biopsies were performed in the setting of diagnostic uncertainty and the risk of misclassification was unlikely to have influenced the results significantly. Secondly, loss to follow up; although hospital records were searched to identify those presenting to other departments in the hospital in order to maximise the identification of SCC cases regardless of such patients' failure to attend the vulval disorders clinic. Finally, the length of study period (3.8 years) may have been insufficient to capture the development of SCC; but this is comparable with follow-up periods in previous studies ranging from 4.7 to 6.2 years. 1, 3, 5, 7 Further limitations include its retrospective design and lack of individual patient data. Consequently, it is not possible to make inferences on causality or independent risks or protective factors for the development of SCC, which would require a prospective observational study design. In addition, the data reflect a tertiary referral centre population, and thus include women with more severe disease. This could result in an increased incidence of SCC, which was not detected.
In conclusion, the management of VLS in our vulval disorders clinic, with intensive initiation therapy and the minimum topical steroid required for maintenance, is associated with a low to negligible incidence of VIN (0.4%) and SCC (0%). However, no conclusions can be drawn on which elements of care or patient related factors may be responsible for this finding. Wound infection is the most common postoperative complication associated with diagnostic skin biopsies. 1 Postoperative wound infections contribute to a significant proportion of infections associated with health care and are an important cause of morbidity and mortality.
2 Furthermore, they contribute to delayed recovery and an increased length of stay in hospital.
This study aimed to determine the rate of postoperative wound infections in dermatology patients undergoing skin biopsies at an Australian tertiary hospital. Secondary objectives included evaluating whether the antibiotics prescribed for prophylaxis and for postoperative wound infection was consistent with local guidelines.
The patients were selected from a pathology database containing the details of all biopsies performed on both dermatology inpatients and outpatients. The biopsy methods included elliptical, punch and shave biopsies. A retrospective assessment of the medical records of all patients 
